Spoken Alpha
CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a Healthcare company operating in Biotechnology with a $5.1M market cap.
Most recent earnings call: Q4 FY24 on Mar 26, 2025.
9 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks CLGN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CLGN.
$ curl https://api.spokenalpha.com/v1/companies/CLGNFAQ
Spoken Alpha indexes CLGN's earnings call transcripts at https://spokenalpha.com/companies/CLGN. Each call links to attributed speakers and parsed analyst Q&A. CollPlant Biotechnologies Ltd's own investor relations page is at https://ir.collplant.com/.
CollPlant Biotechnologies Ltd (CLGN) held its most recent earnings call on 2025-03-26, covering fiscal Q4 2024.
CollPlant Biotechnologies Ltd (CLGN) operates in the Healthcare sector (Biotechnology industry).
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $2.33 | $2.89 | -19.4% | +2.6% | +4.6% |
| Q4 FY2024 | $2.38 | $2.72 | -12.6% | -1.1% | -3.9% |
| Q3 FY2024 | $2.39 | $2.91 | -18.0% | -0.6% | +2.2% |
| Q2 FY2024 | $2.26 | $2.84 | -20.4% | -0.8% | -3.0% |
| Q1 FY2023 | $2.47 | $2.95 | -16.4% | +1.5% | +1.3% |
| Q4 FY2023 |
| $2.35 |
| $2.95 |
| -20.4% |
| +7.3% |
| +4.4% |
| Q3 FY2023 | $2.52 | $2.83 | -10.9% | -0.7% | -1.3% |
| Q2 FY2023 | $2.43 | $2.85 | -14.9% | +2.4% | +2.6% |
| Q1 FY2022 | $2.63 | $3.06 | -14.2% | +1.5% | +3.7% |
| Q4 FY2022 | $2.65 | $3.03 | -12.4% | +7.3% | +5.4% |